Disease Markers

Special Issue on
Advances in Breast Cancer Detection: Imaging, Serum and Tissue Markers, and Germline and Somatic Mutations

Hindawi

CALL FOR PAPERS

Breast cancer (BC), the most diagnosed cancer in women, is a heterogeneous disease with different biological and molecular features. Genetic studies were determinant in providing new surrogate classification of the disease and to lead to personalized treatments. Nowadays, the therapeutic choices rely on both the traditional clinicopathologic parameters, such as TNM staging, histologic grade, hormone receptor status, HER2 and Ki67 expression, and the new molecular intrinsic subtypes classification based on gene expression profiling. The increased availability of several targeting drugs against specific steps of each molecular pathway of cancer cells has led to the need to identify specific predictive biomarkers.

We invite investigators to contribute original research articles as well as review articles that will stimulate the understanding of tumor biology and the development of strategies to improve diagnosis and evaluate prognosis of BC. We are particularly interested in articles describing germline and somatic mutations, advances in serum and tissue markers, current concepts in the diagnostic and prognostic approach of BC, using new tumor markers, molecular imaging techniques of detection, and nucleic acid signatures.

Potential topics include but are not limited to the following:

- ▶ Advances in genetics and molecular features of BC
- ▶ Clinical role of *in situ* tissue markers measurement, including CYC1, GATA3, TIMPs, ALDH, CD133, and ncRNA
- ▶ Role of BRCA1 and BRCA2 and other genes (e.g., TP53, CDH1, PTEN, STK11, and NF1) in cancer susceptibility
- ▶ Advances in the detection of serum tumor markers (TMs), including autoantibodies, Trx1, CSF1, VN, and miRNAs
- ▶ Role of molecular breast imaging (MBI) technology using endogenous or exogenous markers

Authors can submit their manuscripts through the Manuscript Tracking System at http://mts.hindawi.com/submit/journals/dm/abcd/.

Lead Guest Editor

Stefano M. M. Basso, S. Maria degli Angeli Hospital, Pordenone, Italy
drsteba@tin.it

Guest Editors

Franco Lumachi, University of Padua, Padova, Italy
flumachi@unipd.it

Lorenzo Memeo, Mediterranean Institute of Oncology, Viagrande, Italy
lorenzo.memeo@grupposamed.com

Tiziana Perin, CRO Aviano National Cancer Institute, Aviano, Italy
tperin@cro.it

Renato Tozzoli, S. Maria degli Angeli Hospital, Pordenone, Italy
renato.tozzoli@aas5.sanita.fvg.it